---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-041026"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:20:57.756336+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024

## Summary
- Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.
- Cash and short-term investments $58.6M; company believes it can fund operations for at least 12 months.
- CMS granted HCPCS code and TDAPA for DefenCath effective July 1, 2024, providing 5 years of additional ESRD reimbursement.
- Commercial launch of DefenCath in inpatient setting commenced April 15, 2024; outpatient launch expected July 2024.
- Entered 5-year supply contract with ARC Dialysis; FDA meeting on DefenCath in TPN requested, feedback expected Q2 2024.

## SEC filing metadata
- accession: 0001213900-24-041026
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/0001213900-24-041026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/ea020558401-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-041026
- JSON: https://secwatch.observer/filing/0001213900-24-041026.json
- Plain text: https://secwatch.observer/filing/0001213900-24-041026.txt

## Key facts
- Earnings Releases
  CorMedix Inc. reported first quarter ended March 31, 2024 results: net income net loss of $14.5 million, EPS $0.25 per share.
  - Period: first quarter ended March 31, 2024
  - Net income: net loss of $14.5 million
  - EPS: $0.25 per share
  - Result: reported results
  source text: CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/0001213900-24-041026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.